Ignite Creation Date:
2024-05-06 @ 6:35 PM
Last Modification Date:
2024-10-26 @ 2:51 PM
Study NCT ID:
NCT05714202
Status:
RECRUITING
Last Update Posted:
2024-06-20
First Post:
2023-01-27
Brief Title:
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin BCG in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer HR-NMIBC
Sponsor:
Janssen Research Development LLC
Organization:
Janssen Research Development LLC
Organization Data
Organization:
Janssen Research Development LLC
Class:
INDUSTRY
Study ID:
CR109223
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Janssen Research Development LLC
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None